Regenxbio says FDA places clinical hold on RGX-121
Regenxbio says the FDA places a clinical hold on RGX-121 after spine MRI findings and does not expect to resubmit the RGX-121 BLA in the near term.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.